Wells Fargo & Company MN Sells 11,120 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Wells Fargo & Company MN reduced its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 13.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 71,935 shares of the company's stock after selling 11,120 shares during the period. Wells Fargo & Company MN owned about 0.14% of Immunocore worth $2,122,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in IMCR. State Street Corp boosted its holdings in shares of Immunocore by 63.9% during the 3rd quarter. State Street Corp now owns 76,671 shares of the company's stock worth $2,387,000 after buying an additional 29,897 shares during the period. Principal Financial Group Inc. increased its stake in shares of Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after purchasing an additional 109,206 shares during the period. Hennion & Walsh Asset Management Inc. boosted its stake in Immunocore by 125.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock valued at $1,463,000 after purchasing an additional 27,598 shares during the period. Crossmark Global Holdings Inc. grew its holdings in Immunocore by 36.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock valued at $1,121,000 after buying an additional 10,217 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after buying an additional 960 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the company's stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the acquisition, the director now owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IMCR shares. Morgan Stanley reiterated an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. Mizuho reduced their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. JPMorgan Chase & Co. lowered their price objective on Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research report on Monday, April 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Immunocore currently has a consensus rating of "Moderate Buy" and a consensus target price of $60.90.

Immunocore Price Performance

Shares of IMCR stock traded down $0.14 during trading hours on Tuesday, hitting $30.47. 83,735 shares of the company's stock were exchanged, compared to its average volume of 435,614. Immunocore Holdings plc has a 52 week low of $23.15 and a 52 week high of $62.74. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -32.07 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The stock's 50-day moving average is $28.79 and its 200-day moving average is $30.34.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.